Sharma Mani's Form 4 filing
AstraZeneca PLCAZN · filed May 22, 2026
- Accession no.
- 0001104659-26-065693
- Filed
- May 22, 2026
- Trade date
- May 20, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $2.21M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sharma ManiCIK 0002122411 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Ordinary Shares | SSaleDisposed | −11,893 | $185.78F1 | −$2,209,481.54 | 19,262.47 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the sale of shares at a price of GBP139.35, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3332 on May 15, 2026 as published by the Board of Governors of the Federal Reserve System.
Referenced by the price of 1 transaction in Table I.
Remarks
SVP, Group Controller and Head of Global Finance Services